Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates

Company on track for first NDA submission in a gynecologic malignancy in 2026 with a cash balance of $517 million

Related Keywords

Mark Lackner ,Zentalis Pharmaceuticals Inc ,Company Performance Analysis ,Company Performance ,Chief Translational Officer ,Kevin Bunker ,Chief Scientific ,Balance Sheet ,Cash Flow Statement ,New Drug Application ,Biomarker Strategy ,Chief Scientific Officer ,Ynecologic Malignancy ,Cash Balance ,Cash Equivalents ,Iopharmaceutical Company ,Nda Submission ,